Lord's Mark Industries Limited
BBSE:LORDSMARK71.65
INR
-3.45
(-4.59%)
ISIN
INE567L01025
Return %
Stock
S&P 500
1Y
-89.30
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- Sector
- Finance
- Industry
- Investment banks/Brokers
- Address
- Mumbai India
- Website
- lordsmark.com
- Similar Companies
- Business
- Lord's Mark Industries Limited is a diversified Indian conglomerate engaged in the development, manufacturing, and distribution of healthcare diagnostics, medical devices, renewable energy infrastructure, energy-efficient lighting solutions, electric vehicles, paper products, and specialized biotechnology. Founded in 1998 and headquartered in Mumbai, Maharashtra, India, the company operates across several integrated business segments, including Healthcare and MedTech, Renewable Energy and LED Lighting, Electric Mobility, Paper and Stationery, and Financial Intermediation. The company offers a comprehensive range of products and services across its operating divisions: In Vitro Diagnostic (IVD) test kits, rapid antigen and antibody assays, and clinical biochemistry reagents; medical laboratory instrumentation, including semi-automated biochemistry analyzers under the LM-1007 PRO series and hematology analyzers; the Biomescan AI-powered gut microbiome analytics software and preventive genetic screening services; integrated renal care solutions comprising indigenous Renalyx hemodialysis machines, the RenalOS dialysis management platform, and Aureoon network clinics; medical disposables, surgical consumables, and hygiene products under the SafeSehat and MarkoSafe brand names; turnkey E-Smart digital health kiosks and teleconsultation clinics for rural and underserved regions; orthopedic supports, rehabilitation aids, and surgical supplies marketed through Lord's Mark Biotech; on-grid, off-grid, and hybrid solar photovoltaic power plants, rooftop solar installations, solar street lights, and lithium-ion battery energy storage systems; commercial, industrial, and municipal LED lighting fixtures; electric two-wheelers, three-wheelers, and electric vehicle charging equipment manufactured through Lords Automotive Private Limited; continuous computer stationery, paper rolls, and copier paper marketed under the SAPPHIRE brand; and direct insurance broking services through Lord's Mark Insurance Broking Limited. The company supplies healthcare providers, diagnostic laboratories, government departments, municipal corporations, public utilities, commercial enterprises, and retail consumers across India, with an expanding export footprint spanning the SAARC region, the Middle East, Africa, the Caribbean, and Europe. In recent developments, Lord's Mark Industries Limited completed its public listing on the BSE (Ticker: BSE:LORDSMARK) following an NCLT-approved Pre-Packaged Insolvency Resolution Process (PPIRP) reverse merger with Kratos Energy & Infrastructure Limited. Expanding its MedTech and clinical footprint, the company acquired an 85 percent controlling stake in medical technology firm Renalyx to scale AI-integrated, cost-effective dialysis infrastructure, and secured a 30 percent equity stake in Aivita Private Limited to enter the robotic surgery segment. The company has attracted foreign and domestic institutional capital, including equity investments from Goldman Sachs Investments Mauritius I and the Hisaria Group. To accelerate its international expansion, Lord's Mark formed a strategic alliance with ARKALL Holdings Limited to deploy diagnostic and healthcare networks across the Caribbean, while advancing plans for European operational subsidiaries in Switzerland and the United Kingdom. Domestically, the company maintains active technology transfer and research partnerships with institutions including the Indian Institute of Technology Bombay (IIT Bombay) and the Bhabha Atomic Research Centre (BARC) to commercialize patented medical diagnostic and clean energy technologies.